Drug
daratumumab
1 HCP commentary report on clinical trials studying daratumumab. Each report covers what clinicians said in public about one trial, with the source behind every view.
| Trial | Indication | Phase | Claims | HCP sources | Size | Updated | Preview |
|---|---|---|---|---|---|---|---|
| QUINTESSENTIAL-2 NCT06615479 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Multiple myeloma | Phase 3 | 227 | 8 | Focused | 2026-10-09 | Preview |